Financial reports
ARS
2023 FY
Annual report to shareholders
30 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
ARS
2022 FY
Annual report to shareholders
26 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
Current reports
8-K
Other Events
30 Apr 24
8-K
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating
17 Apr 24
8-K
Other Events
16 Apr 24
8-K
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
1 Apr 24
8-K
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
28 Mar 24
8-K
Blinded Safety Review Completed for the First 6 Months of the Phase 2a Clinical Trial Conduct; Recommending Trial Continue Without Modification
13 Mar 24
8-K
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive
4 Mar 24
8-K
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
29 Feb 24
8-K
Other Events
14 Feb 24
8-K
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
1 Feb 24
Registration and prospectus
S-3
Shelf registration
12 Apr 24
S-8
Registration of securities for employees
17 Apr 23
424B3
Prospectus supplement
1 Feb 23
S-3
Shelf registration
23 Jan 23
424B4
Prospectus supplement with pricing info
7 Nov 22
S-1/A
IPO registration (amended)
3 Nov 22
FWP
Free writing prospectus
24 Oct 22
S-1/A
IPO registration (amended)
24 Oct 22
S-1
IPO registration
16 Sep 22
S-8
Registration of securities for employees
4 Nov 21
Proxies
DEF 14A
Definitive proxy
30 Apr 24
DEF 14A
Definitive proxy
26 May 23
PRE 14A
Preliminary proxy
16 May 23
DEF 14A
Definitive proxy
28 Nov 22
PRE 14A
Preliminary proxy
15 Nov 22
DEF 14A
Definitive proxy
18 May 22
PRE 14A
Preliminary proxy
6 May 22
DEF 14A
Definitive proxy
26 Jul 21
DEF 14A
Definitive proxy
15 Jun 21
PRER14A
Preliminary revised proxy
10 Jun 21
Other
EFFECT
Notice of effectiveness
24 Apr 24
EFFECT
Notice of effectiveness
1 Feb 23
CORRESP
Correspondence with SEC
27 Jan 23
UPLOAD
Letter from SEC
25 Jan 23
EFFECT
Notice of effectiveness
7 Nov 22
CORRESP
Correspondence with SEC
3 Nov 22
CORRESP
Correspondence with SEC
3 Nov 22
UPLOAD
Letter from SEC
22 Sep 22
UPLOAD
Letter from SEC
25 Jun 21
CORRESP
Correspondence with SEC
10 Jun 21
Ownership